667 results on '"McGorry, P."'
Search Results
2. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study.
- Author
-
Byrne, Jonah, Healy, Colm, Föcking, Melanie, Susai, Subash, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison, Schäfer, Miriam, Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric, Verma, Swapna, Nieman, Dorien, Woods, Scott, Cornblatt, Barbara, Stone, William, Addington, Jean, Walker, Elaine, Cannon, Tyrone, Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana, Cotter, David, Mathalon, Daniel, Bearden, Carrie, and Cadenhead, Kristin
- Subjects
coagulation ,complement ,high risk ,immune ,model ,prediction ,proteome ,psychosis ,Humans ,Psychotic Disorders ,Female ,Male ,Biomarkers ,Proteomics ,Young Adult ,Adolescent ,Prodromal Symptoms ,Adult ,Disease Progression ,Longitudinal Studies ,Risk - Abstract
Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.
- Published
- 2024
3. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.
- Author
-
Wannan, Cassandra, Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin, McGorry, Patrick, Mittal, Vijay, Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey, Perez, Jesus, Perkins, Diana, Powers, Albert, Roalf, David, Sabb, Fred, Schiffman, Jason, Shah, Jai, Smesny, Stefan, Spark, Jessica, Stone, William, Strauss, Gregory, Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge, Wolf, Daniel, Wolff, Phillip, Wood, Stephen, Yung, Alison, Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo, Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M, Cho, Youngsun, Cotter, David, DAlfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel, Gur, Ruben, Hamilton, Holly, Hoftman, Gil, Jacobs, Grace, Jarcho, Johanna, Ji, Jie, Kohler, Christian, Lalousis, Paris, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero, Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle, Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod, Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce, Walsh, Barbara, Whitford, Thomas, Wigman, Johanna, Yao, Beier, Yuen, Hok, Ahmed, Uzair, Byun, Andrew, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, and Langholm, Carsten
- Subjects
clinical high risk ,consortium ,early detection ,prediction ,prevention ,psychosis ,Humans ,Psychotic Disorders ,Schizophrenia ,Prospective Studies ,Adult ,Prodromal Symptoms ,Young Adult ,International Cooperation ,Adolescent ,Research Design ,Male ,Female - Abstract
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.
- Published
- 2024
4. Prevalence and predictors of admission at the time of presentation in first episode psychosis
- Author
-
Gannon, Louisa, Mullen, Eddie, McGorry, Patrick, and O’Donoghue, Brian
- Published
- 2024
- Full Text
- View/download PDF
5. A prototype software framework for transferable computational health economic models and its early application in youth mental health
- Author
-
Hamilton, Matthew P, Gao, Caroline X, Wiesner, Glen, Filia, Kate M, Menssink, Jana M, Plencnerova, Petra, Baker, David G, McGorry, Patrick D, Parker, Alexandra, Karnon, Jonathan, Cotton, Sue M, and Mihalopoulos, Cathrine
- Subjects
Economics - General Economics ,J.4 - Abstract
We are developing an economic model to explore multiple topics in Australian youth mental health policy. We want that model to be readily transferable to other jurisdictions. We developed a software framework for authoring transparent, reusable and updatable Computational Health Economic Models (CHEMs) (the software files that implement health economic models). We specified framework user requirements of a template CHEM module that facilitates modular model implementations, a simple programming syntax and tools for authoring new CHEM modules, supplying CHEMs with data, reporting reproducible CHEM analyses, searching for CHEM modules and maintaining a CHEM project website. We implemented the framework as six development version code libraries in the programming language R that integrate with online services for software development and research data archiving. We used the framework to author five development version R libraries of CHEM modules focused on utility mapping in youth mental health. These modules provide tools for variable validation, dataset description, multi-attribute instrument scoring, construction of mapping models, reporting of mapping studies and making out of sample predictions. We assessed these CHEM module libraries as mostly meeting transparency, reusability and updatability criteria that we have previously developed, but requiring more detailed documentation and unit testing of individual modules. Our software framework has potential value as a prototype for future tools to support the development of transferable CHEMs., Comment: 16 pages, 3 tables, 1 figure
- Published
- 2023
- Full Text
- View/download PDF
6. A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis
- Author
-
McGorry, Patrick D, Mei, Cristina, Amminger, G Paul, Yuen, Hok Pan, Kerr, Melissa, Spark, Jessica, Wallis, Nicky, Polari, Andrea, Baird, Shelley, Buccilli, Kate, Dempsey, Sarah-Jane A, Ferguson, Natalie, Formica, Melanie, Krcmar, Marija, Quinn, Amelia L, Mebrahtu, Yohannes, Ruslins, Arlan, Street, Rebekah, Wannan, Cassandra, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, and Nelson, Barnaby
- Subjects
Biological Psychology ,Biomedical and Clinical Sciences ,Psychology ,Clinical Trials and Supportive Activities ,Mental Health ,Pediatric ,Serious Mental Illness ,Clinical Research ,Behavioral and Social Science ,Pediatric Research Initiative ,Brain Disorders ,Mental health ,Good Health and Well Being ,Humans ,Female ,Adolescent ,Psychotic Disorders ,Fluoxetine ,Quality of Life ,Antipsychotic Agents ,Recurrence ,Treatment Outcome ,Other Medical and Health Sciences ,Cognitive Sciences ,Clinical sciences ,Clinical and health psychology - Abstract
ImportanceClinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis.ObjectiveTo determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis.Design, setting, and participantsThe Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited.InterventionsStep 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of ω-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months.Main outcomes and measuresGlobal Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-Åsberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates.ResultsThe sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission).Conclusions and relevanceIn this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments.Trial registrationClinicalTrials.gov Identifier: NCT02751632.
- Published
- 2023
7. Baseline data of a sequential multiple assignment randomized trial (STEP study)
- Author
-
Hartmann, Jessica A, Nelson, Barnaby, Amminger, Günther Paul, Spark, Jessica, Yuen, Hok Pan, Kerr, Melissa J, Polari, Andrea, Wallis, Nicky, Blasioli, Julie, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, and McGorry, Patrick D
- Subjects
Prevention ,Clinical Trials and Supportive Activities ,Brain Disorders ,Clinical Research ,Mental Health ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Mental health ,Adolescent ,Antidepressive Agents ,Antipsychotic Agents ,Diagnostic and Statistical Manual of Mental Disorders ,Fatty Acids ,Omega-3 ,Humans ,Psychotic Disorders ,antidepressant medication ,clinical trial ,prodrome ,psychosis ,ultra-high risk ,Clinical Sciences ,Psychology ,Psychiatry - Abstract
AimResearch has shown that preventative intervention in individuals at ultra-high risk of psychosis (UHR) improves symptomatic and functional outcomes. The staged treatment in early psychosis (STEP) trial aims to determine the most effective type, timing and sequence of interventions in the UHR population by sequentially studying the effectiveness of (1) support and problem solving, (2) cognitive-behavioural case management and (3) antidepressant medication with an embedded fast-fail option of (4) omega-3 fatty acids or low-dose antipsychotic medication. This paper presents the recruitment flow and baseline clinical characteristics of the sample.MethodsSTEP is a sequential multiple assignment randomized trial. We present the baseline demographics, clinical characteristics and acceptability and feasibility of this treatment approach as indicated by the flow of participants from first contact up until enrolment into the trial. Recruitment took place between April 2016 and January 2019.ResultsOf 1343, help-seeking young people who were considered for participation, 402 participants were not eligible and 599 declined/disengaged, resulting in a total of 342 participants enrolled in the study. The most common reason for exclusion was an active prescription of antidepressant medication. Eighty-five percent of the enrolled sample had a non-psychotic DSM-5 diagnosis and symptomatic/functional measures showed a moderate level of clinical severity and functional impairment.DiscussionThe present study demonstrates the acceptability and participant's general positive appraisal of sequential treatment. It also shows, in line with other trials in UHR individuals, a significant level of psychiatric morbidity and impairment, demonstrating the clear need for care in this group and that treatment is appropriate.
- Published
- 2022
8. A review of approaches and models in psychopathology conceptualization research
- Author
-
Eaton, Nicholas R., Bringmann, Laura F., Elmer, Timon, Fried, Eiko I., Forbes, Miriam K., Greene, Ashley L., Krueger, Robert F., Kotov, Roman, McGorry, Patrick D., Mei, Cristina, and Waszczuk, Monika A.
- Published
- 2023
- Full Text
- View/download PDF
9. Understanding the complexity, patterns, and correlates of alcohol and other substance use among young people seeking help for mental ill-health
- Author
-
Gao, Caroline X., Filia, Kate M., Bedi, Gillinder, Menssink, Jana M., Brown, Ellie, Rickwood, Debra J., Parker, Alexandra G., Hetrick, Sarah E., Herrman, Helen, Hickie, Ian, Telford, Nic, McGorry, Patrick D., and Cotton, Sue M.
- Published
- 2023
- Full Text
- View/download PDF
10. Correlates of substance use in a large naturalistic cohort of young people with early and emerging psychosis
- Author
-
El-Hage, D., Gao, C. X., Bedi, G., Guerin, A., Francey, S., Stavely, H., Rickwood, D., Telford, N., McGorry, P., Thompson, A., and Brown, Ellie
- Published
- 2023
- Full Text
- View/download PDF
11. Towards a youth mental health paradigm: a perspective and roadmap
- Author
-
Uhlhaas, Peter J., Davey, Christopher G., Mehta, Urvakhsh Meherwan, Shah, Jai, Torous, John, Allen, Nicholas B., Avenevoli, Shelli, Bella-Awusah, Tolulope, Chanen, Andrew, Chen, Eric Y. H., Correll, Christoph U., Do, Kim Q., Fisher, Helen L., Frangou, Sophia, Hickie, Ian B., Keshavan, Matcheri S., Konrad, Kerstin, Lee, Francis S., Liu, Cindy H., Luna, Beatriz, McGorry, Patrick D., Meyer-Lindenberg, Andreas, Nordentoft, Merete, Öngür, Dost, Patton, George C., Paus, Tomáš, Reininghaus, Ulrich, Sawa, Akira, Schoenbaum, Michael, Schumann, Gunter, Srihari, Vinod H., Susser, Ezra, Verma, Swapna K., Woo, T. Wilson, Yang, Lawrence H., Yung, Alison R., and Wood, Stephen J.
- Published
- 2023
- Full Text
- View/download PDF
12. Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial
- Author
-
Allott, Kelly, Yuen, Hok Pan, Baldwin, Lara, O’Donoghue, Brian, Fornito, Alex, Chopra, Sidhant, Nelson, Barnaby, Graham, Jessica, Kerr, Melissa J., Proffitt, Tina-Marie, Ratheesh, Aswin, Alvarez-Jimenez, Mario, Harrigan, Susy, Brown, Ellie, Thompson, Andrew D., Pantelis, Christos, Berk, Michael, McGorry, Patrick D., Francey, Shona M., and Wood, Stephen J.
- Published
- 2023
- Full Text
- View/download PDF
13. Empirically driven transdiagnostic stages in the development of mood, anxiety and psychotic symptoms in a cohort of youth followed from birth
- Author
-
Ratheesh, Aswin, Hammond, Dylan, Gao, Caroline, Marwaha, Steven, Thompson, Andrew, Hartmann, Jessica, Davey, Christopher, Zammit, Stanley, Berk, Michael, McGorry, Patrick, and Nelson, Barnaby
- Published
- 2023
- Full Text
- View/download PDF
14. Gradients of striatal function in antipsychotic-free first-episode psychosis and schizotypy
- Author
-
Oldehinkel, Marianne, Tiego, Jeggan, Sabaroedin, Kristina, Chopra, Sidhant, Francey, Shona M., O’Donoghue, Brian, Cropley, Vanessa, Nelson, Barnaby, Graham, Jessica, Baldwin, Lara, Yuen, Hok Pan, Allott, Kelly, Alvarez-Jimenez, Mario, Harrigan, Susy, Pantelis, Christos, Wood, Stephen J., McGorry, Patrick, Bellgrove, Mark A., and Fornito, Alex
- Published
- 2023
- Full Text
- View/download PDF
15. What Matters to Aboriginal and Torres Strait Islander Youth (WM2Y): a study protocol to develop a national youth well-being measure
- Author
-
Kirsten Howard, Yvonne Cadet-James, Gail Garvey, M Howell, Patrick McGorry, Joan Cunningham, Roxanne Bainbridge, A WILLIAMSON, Michelle Dickson, Tamara L Butler, Darren Garvey, and Kate Mallory Anderson
- Subjects
Medicine - Abstract
Introduction Adolescents face challenges associated with unprecedented environmental, social and technological changes. The impacts of colonisation, intergenerational trauma, racism and socioeconomic disadvantage intensify these challenges for many Aboriginal and Torres Strait Islander adolescents. However, Aboriginal and Torres Strait Islander adolescents also have cultural, spiritual, family and community capital that fosters their well-being.To date, little research has focused on understanding and appropriately measuring the well-being of Aboriginal and Torres Strait Islander adolescents, a pivotal factor in informing and guiding programmes and interventions that support them. This study will identify the domains of well-being and develop a new preference-based well-being measure based on the values and preferences of Aboriginal and Torres Strait Islander youth (aged 12–17 years).Methods and analysis This project will be conducted across three research phases: (1) qualitative exploration of well-being using PhotoYarning and yarns with adult mentors to develop candidate items; (2) Think Aloud study, quantitative survey, psychometric analysis, validity testing of candidate items and finalisation of the descriptive system; and (3) scoring development using a quantitative preference-based approach. A multinomial (conditional) logit framework will be used to analyse responses and generate a scoring algorithm for the new preference-based well-being measure.Ethics and dissemination Ethics approvals have been obtained from: the Human Research Ethics Committees for each state and territory where data are being collected, the institutions where the research is being conducted and from the relevant Departments of Education. The new well-being measure will have wide applicability and can be used in assessing the effectiveness of programmes and services. This new national measure will ensure benefit and positive impact through the ability to identify and measure the aspects of well-being important to and valued by Aboriginal and Torres Strait Islander youth. Results will be published in international peer-reviewed journals and presented at conferences, and summaries will be provided to the study partner organisations and other relevant organisations.
- Published
- 2024
- Full Text
- View/download PDF
16. Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial
- Author
-
Kelly Allott, Hok Pan Yuen, Lara Baldwin, Brian O’Donoghue, Alex Fornito, Sidhant Chopra, Barnaby Nelson, Jessica Graham, Melissa J. Kerr, Tina-Marie Proffitt, Aswin Ratheesh, Mario Alvarez-Jimenez, Susy Harrigan, Ellie Brown, Andrew D. Thompson, Christos Pantelis, Michael Berk, Patrick D. McGorry, Shona M. Francey, and Stephen J. Wood
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract The drivers of cognitive change following first-episode psychosis remain poorly understood. Evidence regarding the role of antipsychotic medication is primarily based on naturalistic studies or clinical trials without a placebo arm, making it difficult to disentangle illness from medication effects. A secondary analysis of a randomised, triple-blind, placebo-controlled trial, where antipsychotic-naive patients with first-episode psychotic disorder were allocated to receive risperidone/paliperidone or matched placebo plus intensive psychosocial therapy for 6 months was conducted. A healthy control group was also recruited. A cognitive battery was administered at baseline and 6 months. Intention-to-treat analysis involved 76 patients (antipsychotic medication group: 37; 18.6Mage [2.9] years; 21 women; placebo group: 39; 18.3Mage [2.7]; 22 women); and 42 healthy controls (19.2Mage [3.0] years; 28 women). Cognitive performance predominantly remained stable (working memory, verbal fluency) or improved (attention, processing speed, cognitive control), with no group-by-time interaction evident. However, a significant group-by-time interaction was observed for immediate recall (p = 0.023), verbal learning (p = 0.024) and delayed recall (p = 0.005). The medication group declined whereas the placebo group improved on each measure (immediate recall: p = 0.024; η p 2 = 0.062; verbal learning: p = 0.015; η p 2 = 0.072 both medium effects; delayed recall: p = 0.001; η p 2 = 0.123 large effect). The rate of change for the placebo and healthy control groups was similar. Per protocol analysis (placebo n = 16, medication n = 11) produced similar findings. Risperidone/paliperidone may worsen verbal learning and memory in the early months of psychosis treatment. Replication of this finding and examination of various antipsychotic agents are needed in confirmatory trials. Antipsychotic effects should be considered in longitudinal studies of cognition in psychosis. Trial registration: Australian New Zealand Clinical Trials Registry ( http://www.anzctr.org.au/ ; ACTRN12607000608460).
- Published
- 2023
- Full Text
- View/download PDF
17. Capturing the clinical complexity in young people presenting to primary mental health services: a data-driven approach
- Author
-
Caroline X. Gao, Nic Telford, Kate M. Filia, Jana M. Menssink, Sabina Albrecht, Patrick D. McGorry, Matthew Hamilton, Mengmeng Wang, Daniel Gan, Dominic Dwyer, Sophie Prober, Isabel Zbukvic, Myriam Ziou, Sue M. Cotton, and Debra J. Rickwood
- Subjects
adolescent ,complexity ,episode of care ,mental health ,mental health services ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Aims The specific and multifaceted service needs of young people have driven the development of youth-specific integrated primary mental healthcare models, such as the internationally pioneering headspace services in Australia. Although these services were designed for early intervention, they often need to cater for young people with severe conditions and complex needs, creating challenges in service planning and resource allocation. There is, however, a lack of understanding and consensus on the definition of complexity in such clinical settings. Methods This retrospective study involved analysis of headspace’s clinical minimum data set from young people accessing services in Australia between 1 July 2018 and 30 June 2019. Based on consultations with experts, complexity factors were mapped from a range of demographic information, symptom severity, diagnoses, illness stage, primary presenting issues and service engagement patterns. Consensus clustering was used to identify complexity subgroups based on identified factors. Multinomial logistic regression was then used to evaluate whether these complexity subgroups were associated with other risk factors. Results A total of 81,622 episodes of care from 76,021 young people across 113 services were analysed. Around 20% of young people clustered into a ‘high complexity’ group, presenting with a variety of complexity factors, including severe disorders, a trauma history and psychosocial impairments. Two moderate complexity groups were identified representing ‘distress complexity’ and ‘psychosocial complexity’ (about 20% each). Compared with the ‘distress complexity’ group, young people in the ‘psychosocial complexity’ group presented with a higher proportion of education, employment and housing issues in addition to psychological distress, and had lower levels of service engagement. The distribution of complexity profiles also varied across different headspace services. Conclusions The proposed data-driven complexity model offers valuable insights for clinical planning and resource allocation. The identified groups highlight the importance of adopting a holistic and multidisciplinary approach to address the diverse factors contributing to clinical complexity. The large number of young people presenting with moderate-to-high complexity to headspace early intervention services emphasises the need for systemic change in youth mental healthcare to ensure the availability of appropriate and timely support for all young people.
- Published
- 2024
- Full Text
- View/download PDF
18. Developing a Theory of Change for a Digital Youth Mental Health Service (Moderated Online Social Therapy): Mixed Methods Knowledge Synthesis Study
- Author
-
Shane Cross, Jennifer Nicholas, Shaminka Mangelsdorf, Lee Valentine, Simon Baker, Patrick McGorry, John Gleeson, and Mario Alvarez-Jimenez
- Subjects
Medicine - Abstract
BackgroundCommon challenges in the youth mental health system include low access, poor uptake, poor adherence, and limited overall effectiveness. Digital technologies offer promise, yet challenges in real-world integration and uptake persist. Moderated Online Social Therapy (MOST) aims to overcome these problems by integrating a comprehensive digital platform into existing youth mental health services. Theory of change (ToC) frameworks can help articulate how and why complex interventions work and what conditions are required for success. ObjectiveThe objective of this study is to create a ToC for MOST to explain how it works, why it works, who benefits and how, and what conditions are required for its success. MethodsWe used a multimethod approach to construct a ToC for MOST. The synthesis aimed to assess the real-world impact of MOST, a digital platform designed to enhance face-to-face youth mental health services, and to guide its iterative refinement. Data were gathered from 2 completed and 4 ongoing randomized controlled trials, 11 pilot studies, and over 1000 co-design sessions using MOST. Additionally, published qualitative findings from diverse clinical contexts and a review of related digital mental health literature were included. The study culminated in an updated ToC framework informed by expert feedback. The final ToC was produced in both narrative and table form and captured components common in program logic and ToC frameworks. ResultsThe MOST ToC captured several assumptions about digital mental health adoption, including factors such as the readiness of young people and service providers to embrace digital platforms. External considerations included high service demand and a potential lack of infrastructure to support integration. Young people and service providers face several challenges and pain points MOST seeks to address, such as limited accessibility, high demand, poor engagement, and a lack of personalized support. Self-determination theory, transdiagnostic psychological treatment approaches, and evidence-based implementation theories and their associated mechanisms are drawn upon to frame the intervention components that make up the platform. Platform usage data are captured and linked to short-, medium-, and long-term intended outcomes, such as reductions in mental health symptoms, improvements in functioning and quality of life, reductions in hospital visits, and reduced overall mental health care costs. ConclusionsThe MOST ToC serves as a strategic framework for refining MOST over time. The creation of the ToC helped guide the development of therapeutic content personalization, user engagement enhancement, and clinician adoption through specialized implementation frameworks. While powerful, the ToC approach has its limitations, such as a lack of standardized methodology and the amount of resourcing required for its development. Nonetheless, it provides an invaluable roadmap for iterative development, evaluation, and scaling of MOST and offers a replicable model for other digital health interventions aiming for targeted, evidence-based impact.
- Published
- 2023
- Full Text
- View/download PDF
19. Prevalence, time trends, and correlates of major depressive episode and other psychiatric conditions among young people amid major social unrest and COVID-19 in Hong Kong: a representative epidemiological study from 2019 to 2022Research in context
- Author
-
Stephanie M.Y. Wong, Eric Y.H. Chen, Y.N. Suen, Corine S.M. Wong, W.C. Chang, Sherry K.W. Chan, Patrick D. McGorry, Craig Morgan, Jim van Os, David McDaid, Peter B. Jones, T.H. Lam, Linda C.W. Lam, Edwin H.M. Lee, Eric Y.H. Tang, Charlie H. Ip, Winky W.K. Ho, Sarah M. McGhee, P.C. Sham, and Christy L.M. Hui
- Subjects
Major depressive episode ,Epidemiological study ,Youth mental health ,Stressful life events ,Social unrest ,COVID-19 ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Hong Kong is among the many populations that has experienced the combined impacts of social unrest and the COVID-19 pandemic. Despite concerns about further deteriorations in youth mental health globally, few epidemiological studies have been conducted to examine the prevalence and correlates of major depressive episode (MDE) and other major psychiatric disorders across periods of population-level changes using diagnostic interviews. Methods: We conducted a territory-wide household-based epidemiological study from 2019 to 2022 targeting young people aged 15–24 years. MDE, generalised anxiety disorder (GAD), panic disorder (PD), and bipolar disorder (BD) were assessed using the Composite International Diagnostic Interview–Screening Scales in 3340 young people. Psychotic disorders were assessed by experienced psychiatrists according to the DSM. Help-seeking patterns were also explored. Findings: 16.6% had any mental disorder (13.7% 12-month MDE, 2.3% BD, 2.1% GAD, 1.0% PD, 0.6% psychotic disorder). The prevalence of MDE increased from 13.2% during period 1 (May 2019–June 2020) to 18.1% during period 2 (July–December 2020), followed by 14.0% during period 3 (January–June 2021) and 13.2% during period 4 (July 2021–June 2022). Different stressors uniquely contributed to MDE across periods: social unrest-related stressors during period 1, COVID-19 stressors during period 2, and personal stressors during periods 3–4. Lower resilience, loneliness, frequent nightmares, and childhood adversity were consistently associated with MDE. Compared to other conditions, those with MDE showed the lowest service utilisation rate (16.7%). Perceiving services to “cost too much” and “talked to friends or relatives instead” were among the major reasons for not seeking help. MDE was also significantly associated with poorer functioning and health-related quality of life. Interpretation: MDE can be sensitive to population-level changes, although its persistently elevated prevalence across the study period is of concern. Efforts to mitigate their impacts on youth mental health alongside personal risk factors are needed. Further work is required to increase the availability and acceptability of youth-targeted mental health services. Funding: Food and Health Bureau (HKSAR Government).
- Published
- 2023
- Full Text
- View/download PDF
20. The clinical characterization of the patient with primary psychosis aimed at personalization of management.
- Author
-
Maj, Mario, van Os, Jim, De Hert, Marc, Gaebel, Wolfgang, Galderisi, Silvana, Green, Michael, Guloksuz, Sinan, Harvey, Philip, Jones, Peter, Malaspina, Dolores, McGorry, Patrick, Miettunen, Jouko, Murray, Robin, Nuechterlein, Keith, Peralta, Victor, Thornicroft, Graham, van Winkel, Ruud, and Ventura, Joseph
- Subjects
Primary psychosis ,environmental exposures ,family history ,internalized stigma ,negative dimension ,neurocognition ,obstetric complications ,personalization of treatment ,physical comorbidities ,positive dimension ,practical needs ,protective factors ,psychiatric antecedents ,psychiatric comorbidities ,psychosocial interventions ,recovery ,resilience ,schizophrenia ,social cognition ,social functioning - Abstract
The current management of patients with primary psychosis worldwide is often remarkably stereotyped. In almost all cases an antipsychotic medica-tion is prescribed, with second-generation antipsychotics usually preferred to first-generation ones. Cognitive behavioral therapy is rarely used in the vast majority of countries, although there is evidence to support its efficacy. Psychosocial interventions are often provided, especially in chronic cases, but those applied are frequently not validated by research. Evidence-based family interventions and supported employment programs are seldom implemented in ordinary practice. Although the notion that patients with primary psychosis are at increased risk for cardiovascular diseases and diabetes mellitus is widely shared, it is not frequent that appropriate measures be implemented to address this problem. The view that the management of the patient with primary psychosis should be personalized is endorsed by the vast majority of clinicians, but this personalization is lacking or inadequate in most clinical contexts. Although many mental health services would declare themselves recovery-oriented, it is not common that a focus on empowerment, identity, meaning and resilience is ensured in ordinary practice. The present paper aims to address this situation. It describes systematically the salient domains that should be considered in the characterization of the individual patient with primary psychosis aimed at personalization of management. These include positive and negative symptom dimensions, other psychopathological components, onset and course, neurocognition and social cognition, neurodevelopmental indicators; social functioning, quality of life and unmet needs; clinical staging, antecedent and concomitant psychiatric conditions, physical comorbidities, family history, history of obstetric complications, early and recent environmental exposures, protective factors and resilience, and internalized stigma. For each domain, simple assessment instruments are identified that could be considered for use in clinical practice and included in standardized decision tools. A management of primary psychosis is encouraged which takes into account all the available treatment modalities whose efficacy is supported by research evidence, selects and modulates them in the individual patient on the basis of the clinical characterization, addresses the patients needs in terms of employment, housing, self-care, social relationships and education, and offers a focus on identity, meaning and resilience.
- Published
- 2021
21. Gradients of striatal function in antipsychotic-free first-episode psychosis and schizotypy
- Author
-
Marianne Oldehinkel, Jeggan Tiego, Kristina Sabaroedin, Sidhant Chopra, Shona M. Francey, Brian O’Donoghue, Vanessa Cropley, Barnaby Nelson, Jessica Graham, Lara Baldwin, Hok Pan Yuen, Kelly Allott, Mario Alvarez-Jimenez, Susy Harrigan, Christos Pantelis, Stephen J. Wood, Patrick McGorry, Mark A. Bellgrove, and Alex Fornito
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Both psychotic illness and subclinical psychosis-like experiences (PLEs) have been associated with cortico-striatal dysfunction. This work has largely relied on a discrete parcellation of the striatum into distinct functional areas, but recent evidence suggests that the striatum comprises multiple overlapping and smoothly varying gradients (i.e., modes) of functional organization. Here, we investigated two of these functional connectivity modes, previously associated with variations in the topographic patterning of cortico-striatal connectivity (first-order gradient), and dopaminergic innervation of the striatum (second-order gradient), and assessed continuities in striatal function from subclinical to clinical domains. We applied connectopic mapping to resting-state fMRI data to obtain the first-order and second-order striatal connectivity modes in two distinct samples: (1) 56 antipsychotic-free patients (26 females) with first-episode psychosis (FEP) and 27 healthy controls (17 females); and (2) a community-based cohort of 377 healthy individuals (213 females) comprehensively assessed for subclinical PLEs and schizotypy. The first-order “cortico-striatal” and second-order “dopaminergic” connectivity gradients were significantly different in FEP patients compared to controls bilaterally. In the independent sample of healthy individuals, variations in the left first-order “cortico-striatal” connectivity gradient were associated with inter-individual differences in a factor capturing general schizotypy and PLE severity. The presumed cortico-striatal connectivity gradient was implicated in both subclinical and clinical cohorts, suggesting that variations in its organization may represent a neurobiological trait marker across the psychosis continuum. Disruption of the presumed dopaminergic gradient was only noticeable in patients, suggesting that neurotransmitter dysfunction may be more apparent to clinical illness.
- Published
- 2023
- Full Text
- View/download PDF
22. Empirically driven transdiagnostic stages in the development of mood, anxiety and psychotic symptoms in a cohort of youth followed from birth
- Author
-
Aswin Ratheesh, Dylan Hammond, Caroline Gao, Steven Marwaha, Andrew Thompson, Jessica Hartmann, Christopher Davey, Stanley Zammit, Michael Berk, Patrick McGorry, and Barnaby Nelson
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Staging models with transdiagnostic validity across mood, psychotic, and anxiety disorders could advance early intervention efforts as well as our understanding of the common underpinnings of such psychopathology. However, there are few well-supported operationalisations for such transdiagnostic models, particularly in community-based samples. We aimed to explore the inter-relationships among mood, psychotic, and anxiety symptom stages, and their common risk factors to develop data-informed transdiagnostic stages. We included participants from the Avon Longitudinal Study of Parents and Children (ALSPAC), a prospective ongoing birth cohort study. We developed operational thresholds for stages of depressive, hypomanic, anxiety, and psychotic symptoms based on the existing literature, refined further by expert consensus. We selected 1b level as the primary stage or outcome of interest. This represents moderate symptoms that are likely to be associated with the onset of the need for clinical mental health care. We used questionnaire and clinic data completed by young people ages 18 and 21 years. We used descriptive methods and network analyses to examine the overlap among Stage 1b psychopathology. We then examined the patterns of relationships between several risk factors and 1b stages using logistic regressions. Among 3269 young people with data available to determine all symptom stages, 64.3% were female and 96% Caucasian. Descriptive and network analyses indicated that 1b level depressive, anxiety, and psychotic symptom stages were inter-related while hypomania was not. Similarly, anxiety, depressive, and psychotic 1b stages were associated with the female sex, more emotional and behavioral difficulties in early adolescence, and life events in late adolescence. Hypomania was not related to any of these risk factors. Given their inter-relationships and similar risk factors, anxiety, psychotic and depressive, symptoms could be combined to form a transdiagnostic stage in this cohort. Such empirical transdiagnostic stages could help with prognostication and indicated prevention in youth mental health.
- Published
- 2023
- Full Text
- View/download PDF
23. The SPEAK study rationale and design: A linguistic corpus-based approach to understanding thought disorder
- Author
-
Bayer, J.M.M., Spark, J., Krcmar, M., Formica, M., Gwyther, K., Srivastava, A., Selloni, A., Cotter, M., Hartmann, J., Polari, A., Bilgrami, Z.R., Sarac, C., Lu, A., Yung, Alison R., McGowan, A., McGorry, P., Shah, J.L., Cecchi, G.A., Mizrahi, R., Nelson, B., and Corcoran, C.M.
- Published
- 2023
- Full Text
- View/download PDF
24. EMPOWERED trial: protocol for a randomised control trial of digitally supported, highly personalised and measurement-based care to improve functional outcomes in young people with mood disorders
- Author
-
Daniel F Hermens, Adam J Guastella, Jan Scott, Elizabeth M Scott, Ian B Hickie, Eoin Killackey, Cathrine Mihalopoulos, Maree L Hackett, Frank Iorfino, Alice Lo, Patrick McGorry, Alissa Nichles, Natalia Zmicerevska, Jacob J Crouse, Cathrin Rohleder, Yun Ju Christine Song, Blake Hamilton, Dagmar Koethe, F Markus Leweke, Sarah McKenna, William Capon, Min K Chong, Melissa Aji, Carla Gorban, Robert Battisti, Mark Yim, Bradley Whitwell, Alison Crowley, Donna Fowler, Elana Volanakis, Vicki Papageorgopoulos, Matilda Russel, and Elizabeth Phung
- Subjects
Medicine - Abstract
Objectives Many adolescents and young adults with emerging mood disorders do not achieve substantial improvements in education, employment, or social function after receiving standard youth mental health care. We have developed a new model of care referred to as ‘highly personalised and measurement-based care’ (HP&MBC). HP&MBC involves repeated assessment of multidimensional domains of morbidity to enable continuous and personalised clinical decision-making. Although measurement-based care is common in medical disease management, it is not a standard practice in mental health. This clinical effectiveness trial tests whether HP&MBC, supported by continuous digital feedback, delivers better functional improvements than standard care and digital support.Method and analysis This controlled implementation trial is a PROBE study (Prospective, Randomised, Open, Blinded End-point) that comprises a multisite 24-month, assessor-blinded, follow-up study of 1500 individuals aged 15–25 years who present for mental health treatment. Eligible participants will be individually randomised (1:1) to 12 months of HP&MBC or standardised clinical care. The primary outcome measure is social and occupational functioning 12 months after trial entry, assessed by the Social and Occupational Functioning Assessment Scale. Clinical and social outcomes for all participants will be monitored for a further 12 months after cessation of active care.Ethics and dissemination This clinical trial has been reviewed and approved by the Human Research Ethics Committee of the Sydney Local Health District (HREC Approval Number: X22-0042 & 2022/ETH00725, Protocol ID: BMC-YMH-003-2018, protocol version: V.3, 03/08/2022). Research findings will be disseminated through peer-reviewed journals, presentations at scientific conferences, and to user and advocacy groups. Participant data will be deidentified.Trial registration number ACTRN12622000882729.
- Published
- 2023
- Full Text
- View/download PDF
25. Disruptions in white matter microstructure associated with impaired visual associative memory in schizophrenia-spectrum illness
- Author
-
Wannan, Cassandra M. J., Bartholomeusz, Cali F., Pantelis, Christos, Di Biase, Maria A., Syeda, Warda T., Chakravarty, M. Mallar, Bousman, Chad A., Everall, Ian P., McGorry, Patrick D., Zalesky, Andrew, and Cropley, Vanessa L.
- Published
- 2022
- Full Text
- View/download PDF
26. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
- Author
-
Subash Raj Susai, Colm Healy, David Mongan, Meike Heurich, Jonah F. Byrne, Mary Cannon, Gerard Cagney, Kieran Wynne, Connie Markulev, Miriam R. Schäfer, Maximus Berger, Nilufar Mossaheb, Monika Schlögelhofer, Stefan Smesny, Ian B. Hickie, Gregor E. Berger, Eric Y. H. Chen, Lieuwe de Haan, Dorien H. Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Rebekah Street, Andrew Thompson, Alison Ruth Yung, Barnaby Nelson, Patrick D. McGorry, Melanie Föcking, G. Paul Amminger, and David Cotter
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins.
- Published
- 2022
- Full Text
- View/download PDF
27. Social inclusion, intersectionality, and profiles of vulnerable groups of young people seeking mental health support
- Author
-
Filia, K., Menssink, J., Gao, C. X., Rickwood, D., Hamilton, M., Hetrick, S. E., Parker, A. G., Herrman, H., Hickie, I., Sharmin, S., McGorry, P. D., and Cotton, S. M.
- Published
- 2022
- Full Text
- View/download PDF
28. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
- Author
-
Susai, Subash Raj, Healy, Colm, Mongan, David, Heurich, Meike, Byrne, Jonah F., Cannon, Mary, Cagney, Gerard, Wynne, Kieran, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y. H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Yung, Alison Ruth, Nelson, Barnaby, McGorry, Patrick D., Föcking, Melanie, Amminger, G. Paul, and Cotter, David
- Published
- 2022
- Full Text
- View/download PDF
29. Sixteen years of innovation in youth mental healthcare: Outcomes for young people attending Australia's headspace centre services.
- Author
-
Debra Rickwood, Juliet McEachran, Anna Saw, Nic Telford, Jason Trethowan, and Patrick McGorry
- Subjects
Medicine ,Science - Abstract
Australia's headspace initiative is world-leading in nation-wide youth mental healthcare reform for young people aged 12 to 25 years, now with 16 years of implementation. This paper examines changes in the key outcomes of psychological distress, psychosocial functioning, and quality of life for young people accessing headspace centres across Australia for mental health problems. Routinely collected data from headspace clients commencing an episode of care within the data collection period, 1 April 2019 to 30 March 2020, and at 90-day follow-up were analysed. Participants came from the 108 fully-established headspace centres across Australia, and comprised 58,233 young people aged 12-25 years first accessing headspace centres for mental health problems during the data collection period. Main outcome measures were self-reported psychological distress and quality of life, and clinician-reported social and occupational functioning. Most headspace mental health clients presented with depression and anxiety issues (75.21%). There were 35.27% with a diagnosis: overall, 21.74% diagnosed with anxiety, 18.51% with depression, and 8.60% were sub-syndromal. Younger males were more likely to present for anger issues. Cognitive behavioural therapy was the most common treatment. There were significant improvements in all outcome scores over time (P
- Published
- 2023
- Full Text
- View/download PDF
30. Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis
- Author
-
Stefania Tognin, Ana Catalan, Matthew J. Kempton, Barnaby Nelson, Patrick McGorry, Anita Riecher-Rössler, Rodrigo Bressan, Neus Barrantes-Vidal, Marie-Odile Krebs, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P. F. Rutten, Jim van Os, Lieuwe de Haan, Mark van der Gaag, Philip McGuire, and Lucia R. Valmaggia
- Subjects
Adverse childhood experiences ,clinical high risk for psychosis ,education ,Psychiatry ,RC435-571 - Abstract
Abstract Background Adverse childhood experiences (ACE) can affect educational attainments, but little is known about their impact on educational achievements in people at clinical high risk of psychosis (CHR). Methods In total, 344 CHR individuals and 67 healthy controls (HC) were recruited as part of the European Community’s Seventh Framework Programme-funded multicenter study the European Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI). The brief version of the Child Trauma Questionnaire was used to measure ACE, while educational attainments were assessed using a semi-structured interview. Results At baseline, compared with HC, the CHR group spent less time in education and had higher rates of ACE, lower rates of employment, and lower estimated intelligence quotient (IQ). Across both groups, the total number of ACE was associated with fewer days in education and lower level of education. Emotional abuse was associated with fewer days in education in HC. Emotional neglect was associated with a lower level of education in CHR, while sexual abuse was associated with a lower level of education in HC. In the CHR group, the total number of ACE, physical abuse, and neglect was significantly associated with unemployment, while emotional neglect was associated with employment. Conclusions ACE are strongly associated with developmental outcomes such as educational achievement. Early intervention for psychosis programs should aim at integrating specific interventions to support young CHR people in their educational and vocational recovery. More generally, public health and social interventions focused on the prevention of ACE (or reduce their impact if ACE occur) are recommended.
- Published
- 2023
- Full Text
- View/download PDF
31. Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosis
- Author
-
Wang, Ya, Braam, Esmee E., Wannan, Cassandra M. J., Van Rheenen, Tamsyn E., Chan, Raymond C. K., Nelson, Barnaby, McGorry, Patrick D., Yung, Alison R., Lin, Ashleigh, Brewer, Warrick J., Koutsogiannis, John, Wood, Stephen J., Velakoulis, Dennis, Pantelis, Christos, and Cropley, Vanessa L.
- Published
- 2021
- Full Text
- View/download PDF
32. The associations between migrant status and ethnicity and the identification of individuals at ultra-high risk for psychosis and transition to psychosis: a systematic review
- Author
-
Moore, Danielle, Castagnini, Emily, Mifsud, Nathan, Geros, Hellen, Sizer, Holly, Addington, Jean, van der Gaag, Mark, Nelson, Barnaby, McGorry, Patrick, and O’Donoghue, Brian
- Published
- 2021
- Full Text
- View/download PDF
33. Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients
- Author
-
Nelson, Barnaby, Amminger, G Paul, Yuen, Hok Pan, Wallis, Nicky, Kerr, Melissa J, Dixon, Lisa, Carter, Cameron, Loewy, Rachel, Niendam, Tara A, Shumway, Martha, Morris, Sarah, Blasioli, Julie, and McGorry, Patrick D
- Subjects
Prevention ,Mental Health ,Clinical Research ,Behavioral and Social Science ,Patient Safety ,Clinical Trials and Supportive Activities ,Brain Disorders ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,6.6 Psychological and behavioural ,Mental health ,Adolescent ,Adult ,Antidepressive Agents ,Child ,Cognitive Behavioral Therapy ,Combined Modality Therapy ,Early Medical Intervention ,Humans ,Psychotic Disorders ,Vulnerable Populations ,Young Adult ,antidepressant medication ,clinical trial ,prodrome ,psychosis ,ultra high risk ,Clinical Sciences ,Psychology ,Psychiatry - Abstract
AimPrevious research indicates that preventive intervention is likely to benefit patients "at risk" of psychosis, in terms of functional improvement, symptom reduction and delay or prevention of onset of threshold psychotic disorder. The primary aim of the current study is to test outcomes of ultra high risk (UHR) patients, primarily functional outcome, in response to a sequential intervention strategy consisting of support and problem solving (SPS), cognitive-behavioural case management and antidepressant medication. A secondary aim is to test biological and psychological variables that moderate and mediate response to this sequential treatment strategy.MethodsThis is a sequential multiple assignment randomised trial (SMART) consisting of three steps: Step 1: SPS (1.5 months); Step 2: SPS vs Cognitive Behavioural Case Management (4.5 months); Step 3: Cognitive Behavioural Case Management + Antidepressant Medication vs Cognitive Behavioural Case Management + Placebo (6 months). The intervention is of 12 months duration in total and participants will be followed up at 18 months and 24 months post baseline.ConclusionThis paper reports on the rationale and protocol of the Staged Treatment in Early Psychosis (STEP) study. With a large sample of 500 UHR participants this study will investigate the most effective type and sequence of treatments for improving functioning and reducing the risk of developing psychotic disorder in this clinical population.
- Published
- 2018
34. A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAstER) study
- Author
-
Brian O'Donoghue, Nathan Mifsud, Emily Castagnini, Alison Langstone, Andrew Thompson, Eoin Killackey, and Patrick McGorry
- Subjects
Psychotic disorders ,antipsychotics ,metabolic syndrome ,obesity ,schizophrenia ,Psychiatry ,RC435-571 - Abstract
Background Factors that contribute to the early mortality observed in psychotic disorders, specifically obesity, smoking and sedentary behaviour, occur early in the disorder. Aims We aimed to determine whether the integration of a physical health nurse in the care of young people with first-episode psychosis could prevent clinically significant weight gain (≥7% body weight). Secondary outcomes included rates of smoking, metabolic syndrome and sedentary behaviour. Method In this single-blind, randomised controlled trial, participants who had received under 4 weeks of antipsychotic medication were randomly allocated to either the intervention (addition of a physical health nurse to their care) or treatment as usual (TAU) for 12 weeks. Results Of the 77 participants, there were follow-up data for 86.8% (n = 33) of the intervention group and 82.1% (n = 32) of the TAU group. After 12 weeks, 27.3% of the intervention group experienced clinically significant weight gain compared with 34.4% of the TAU group (odds ratio 0.72, 95% CI 0.25–2.06, P = 0.54). After 6 months, 40.7% of the intervention group gained clinically significant weight compared with 44.1% of the TAU group (P = 0.79). There was no difference in mean change in weight between groups after 12 weeks (2.6 kg v. 2.9 kg, P = 0.87) or 6 months (3.6 kg v. 4.3 kg, P = 0.64). There were no differences in the rates of tobacco smoking cessation, prevalence of metabolic syndrome or physical activity levels. Conclusions This intervention failed to prevent the metabolic complications that are highly prevalent in psychotic disorders in the short to medium term, indicating that more intensive interventions are required.
- Published
- 2022
- Full Text
- View/download PDF
35. Heschl’s gyrus duplication pattern and clinical characteristics in borderline personality disorder: A preliminary study
- Author
-
Tsutomu Takahashi, Daiki Sasabayashi, Dennis Velakoulis, Michio Suzuki, Patrick D. McGorry, Christos Pantelis, and Andrew M. Chanen
- Subjects
superior temporal gyrus ,gyrification ,sulco-gyral pattern ,externalizing behavior ,disruptive behavior disorders ,magnetic resonance imaging ,Psychiatry ,RC435-571 - Abstract
Inter-individual variations in the sulco-gyral pattern of Heschl’s gyrus (HG) might contribute to emotional processing. However, it remains largely unknown whether borderline personality disorder (BPD) patients exhibit an altered HG gyrification pattern, compared with healthy individuals, and whether such a brain morphological feature, if present, might contribute to their clinical characteristics. The present study used magnetic resonance imaging to investigate the distribution of HG gyrification patterns (single or duplicated) and their relationship to clinical characteristics in teenage BPD patients with minimal treatment exposure. No significant difference was noted for the prevalence of HG patterns between 20 BPD and 20 healthy participants. However, the BPD participants with left duplicated HG were characterized by higher prevalence of comorbid disruptive behavior disorders, with higher externalizing score compared with those with left single HG. Our preliminary results suggest that neurodevelopmental pathology associated with gyral formation might be implicated in the neurobiology of early BPD, especially for emotional and behavioral control.
- Published
- 2022
- Full Text
- View/download PDF
36. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
- Author
-
Velthorst, Eva, Mollon, Josephine, Murray, Robin M., de Haan, Lieuwe, Germeys, Inez Myin, Glahn, David C., Arango, Celso, van der Ven, Els, Di Forti, Marta, Bernardo, Miguel, Guloksuz, Sinan, Delespaul, Philippe, Mezquida, Gisela, Amoretti, Silvia, Bobes, Julio, Saiz, Pilar A., García-Portilla, María Paz, Santos, José Luis, Jiménez-López, Estela, Sanjuan, Julio, Aguilar, Eduardo J., Arrojo, Manuel, Carracedo, Angel, López, Gonzalo, González-Peñas, Javier, Parellada, Mara, Atbaşoğlu, Cem, Saka, Meram Can, Üçok, Alp, Alptekin, Köksal, Akdede, Berna, Binbay, Tolga, Altınyazar, Vesile, Ulaş, Halis, Yalınçetin, Berna, Gümüş-Akay, Güvem, Beyaz, Burçin Cihan, Soygür, Haldun, Cankurtaran, Eylem Şahin, Kaymak, Semra Ulusoy, Maric, Nadja P., Mihaljevic, Marina M., Petrovic, Sanja Andric, Mirjanic, Tijana, Del-Ben, Cristina Marta, Ferraro, Laura, Gayer-Anderson, Charlotte, Jones, Peter B., Jongsma, Hannah E., Kirkbride, James B., La Cascia, Caterina, Lasalvia, Antonio, Tosato, Sarah, Llorca, Pierre-Michel, Menezes, Paulo Rossi, Morgan, Craig, Quattrone, Diego, Menchetti, Marco, Selten, Jean-Paul, Szöke, Andrei, Tarricone, Ilaria, Tortelli, Andrea, McGuire, Philip, Valmaggia, Lucia, Kempton, Matthew J., van der Gaag, Mark, Riecher-Rössler, Anita, Bressan, Rodrigo A., Barrantes-Vidal, Neus, Nelson, Barnaby, McGorry, Patrick, Pantelis, Chris, Krebs, Marie-Odile, Ruhrmann, Stephan, Sachs, Gabriele, Rutten, Bart P. F., van Os, Jim, Alizadeh, Behrooz Z., van Amelsvoort, Therese, Bartels-Velthuis, Agna A., Bruggeman, Richard, van Beveren, Nico J., Luykx, Jurjen J., Cahn, Wiepke, Simons, Claudia J. P., Kahn, Rene S., Schirmbeck, Frederike, van Winkel, Ruud, and Reichenberg, Abraham
- Published
- 2021
- Full Text
- View/download PDF
37. Symptomatic, functional and service utilization outcomes of migrants with a first episode of psychosis
- Author
-
Maguire, James, Mifsud, Nathan, Seiler, Natalie, Nguyen, Tony, Sizer, Holly, McGorry, Patrick, and O’Donoghue, Brian
- Published
- 2021
- Full Text
- View/download PDF
38. Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
- Author
-
Nicholas Cheng, Alison McLaverty, Barnaby Nelson, Connie Markulev, Miriam R. Schäfer, Maximus Berger, Nilufar Mossaheb, Monika Schlögelhofer, Stefan Smesny, Ian B. Hickie, Gregor E. Berger, Eric Y. H. Chen, Lieuwe de Haan, Dorien H. Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Rebekah Street, Andrew Thompson, Hok Pan Yuen, Robert Hester, Alison Ruth Yung, Patrick D. McGorry, Kelly Allott, and G. Paul Amminger
- Subjects
Cognition ,clinical high risk ,early intervention ,randomised controlled trial ,psychotic disorders ,Psychiatry ,RC435-571 - Abstract
Background Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ultra-high risk for psychosis. However, few interventions target cognitive functioning in this population. Aims To investigate whether omega-3 polyunsaturated fatty acid (n−3 PUFA) supplementation improves cognitive functioning among individuals at ultra-high risk for psychosis. Method Data (N = 225) from an international, multi-site, randomised controlled trial (NEURAPRO) were analysed. Participants were given omega-3 supplementation (eicosapentaenoic acid and docosahexaenoic acid) or placebo over 6 months. Cognitive functioning was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS). Mixed two-way analyses of variance were computed to compare the change in cognitive performance between omega-3 supplementation and placebo over 6 months. An additional biomarker analysis explored whether change in erythrocyte n−3 PUFA levels predicted change in cognitive performance. Results The placebo group showed a modest greater improvement over time than the omega-3 supplementation group for motor speed (ηp2 = 0.09) and BACS composite score (ηp2 = 0.21). After repeating the analyses without individuals who transitioned, motor speed was no longer significant (ηp2 = 0.02), but the composite score remained significant (ηp2 = 0.02). Change in erythrocyte n-3 PUFA levels did not predict change in cognitive performance over 6 months. Conclusions We found no evidence to support the use of omega-3 supplementation to improve cognitive functioning in ultra-high risk individuals. The biomarker analysis suggests that this finding is unlikely to be attributed to poor adherence or consumption of non-trial n−3 PUFAs.
- Published
- 2022
- Full Text
- View/download PDF
39. Convergence Science Arrives: How Does It Relate to Psychiatry?
- Author
-
Eyre, Harris A, Lavretsky, Helen, Forbes, Malcolm, Raji, Cyrus, Small, Gary, McGorry, Patrick, Baune, Bernhard T, and Reynolds, Charles
- Subjects
Curriculum and Pedagogy ,Education ,Humans ,Interdisciplinary Studies ,Psychiatry ,Science ,Translational Research ,Biomedical ,Curriculum and pedagogy - Published
- 2017
40. The Lancet PsychiatryCommission on youth mental health
- Author
-
McGorry, Patrick D, Mei, Cristina, Dalal, Naeem, Alvarez-Jimenez, Mario, Blakemore, Sarah-Jayne, Browne, Vivienne, Dooley, Barbara, Hickie, Ian B, Jones, Peter B, McDaid, David, Mihalopoulos, Cathrine, Wood, Stephen J, El Azzouzi, Fatima Azzahra, Fazio, Jessica, Gow, Ella, Hanjabam, Sadam, Hayes, Alan, Morris, Amelia, Pang, Elina, Paramasivam, Keerthana, Quagliato Nogueira, Isabella, Tan, Jimmy, Adelsheim, Steven, Broome, Matthew R, Cannon, Mary, Chanen, Andrew M, Chen, Eric Y H, Danese, Andrea, Davis, Maryann, Ford, Tamsin, Gonsalves, Pattie P, Hamilton, Matthew P, Henderson, Jo, John, Ann, Kay-Lambkin, Frances, Le, Long K-D, Kieling, Christian, Mac Dhonnagáin, Niall, Malla, Ashok, Nieman, Dorien H, Rickwood, Debra, Robinson, Jo, Shah, Jai L, Singh, Swaran, Soosay, Ian, Tee, Karen, Twenge, Jean, Valmaggia, Lucia, van Amelsvoort, Therese, Verma, Swapna, Wilson, Jon, Yung, Alison, Iyer, Srividya N, and Killackey, Eóin
- Published
- 2024
- Full Text
- View/download PDF
41. Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study
- Author
-
Chopra, Sidhant, Fornito, Alex, Francey, Shona M., O’Donoghue, Brian, Cropley, Vanessa, Nelson, Barnaby, Graham, Jessica, Baldwin, Lara, Tahtalian, Steven, Yuen, Hok Pan, Allott, Kelly, Alvarez-Jimenez, Mario, Harrigan, Susy, Sabaroedin, Kristina, Pantelis, Christos, Wood, Stephen J., and McGorry, Patrick
- Published
- 2021
- Full Text
- View/download PDF
42. Clinical and functional characteristics of a subsample of young people presenting for primary mental healthcare at headspace services across Australia
- Author
-
Filia, K., Rickwood, D., Menssink, J., Gao, C. X., Hetrick, S., Parker, A., Hamilton, M., Hickie, I., Herrman, H., Telford, N., Sharmin, S., McGorry, P., and Cotton, S.
- Published
- 2021
- Full Text
- View/download PDF
43. The association between migrant status and transition in an ultra-high risk for psychosis population
- Author
-
O’Donoghue, Brian, Geros, Hellen, Sizer, Holly, Addington, Jean, Amminger, G. Paul, Beaden, Carrie E., Cadenhead, Kristin S., Cannon, Tyrone D., Cornblatt, Barbara A., Berger, Gregor Emanuel, Chen, Eric Y. H., de Haan, Lieuwe, Hartmann, Jessica A., Hickie, Ian B., Ising, Helga K., Lavoie, Suzie, Lin, Ashleigh, Markulev, Connie, Mathalon, Daniel H., McGlashan, Thomas H., Mifsud, Nathan G., Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Perkins, Diana O., Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Seidman, Larry J., Smesny, Stephan, Thompson, Andrew, Tsuang, Ming T., van der Gaag, Mark, Verma, Swapna, Walker, Elaine F., Wood, Stephen J., Woods, Scott W., Yuen, Hok Pan, Yung, Alison Ruth, McGorry, Patrick D., and Nelson, Barnaby
- Published
- 2021
- Full Text
- View/download PDF
44. Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis
- Author
-
Emily P. Hedges, Hannah Dickson, Stefania Tognin, Gemma Modinos, Mathilde Antoniades, Mark van der Gaag, Lieuwe de Haan, Patrick McGorry, Christos Pantelis, Anita Riecher-Rössler, Rodrigo Bressan, Neus Barrantes-Vidal, Marie-Odile Krebs, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P. Rutten, Jim van Os, Lucia R. Valmaggia, Philip McGuire, and Matthew J. Kempton
- Subjects
Cognition ,Verbal fluency ,Prodrome ,Transition ,Early intervention ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Robust deficits in cognitive functioning are present in people with psychosis and are evident in the early stages of the disorder. Impairments in verbal memory and verbal fluency are reliably seen in individuals at clinical high-risk for psychosis (CHR) compared to healthy populations. As previous studies have shown a relationship between cognition and longer-term outcomes in schizophrenia, the aim of this paper was to explore whether verbal memory and verbal fluency performance predicted outcomes in a large CHR sample recruited as part of the EU-GEI High Risk Study. Participants included 316 CHR individuals, 90.8% of whom were not currently on antipsychotic medication, and 60 healthy controls. Verbal memory and verbal fluency performance were measured at baseline. At two-year follow-up, CHR individuals were assessed by three different outcome measures, those who did and did not (1) transition to psychosis, (2) experience burdening impairment or disabilities, or (3) remit clinically from CHR status. Individuals with CHR displayed significant verbal memory and verbal fluency deficits at baseline compared to healthy controls (Hedges' g effect size = 0.24 to 0.66). There were no significant differences in cognitive performance of those who did and did not transition to psychosis. However, impaired immediate verbal recall predicted both functional disability and non-remission from the CHR state. Results remained significant when analyses were restricted to only include antipsychotic-free CHR participants. These findings may inform the development of early interventions designed to improve cognitive deficits in the early stages of psychosis.
- Published
- 2022
- Full Text
- View/download PDF
45. A Dynamical Systems View of Psychiatric Disorders—Practical Implications: A Review.
- Author
-
Scheffer, Marten, Bockting, Claudi L., Borsboom, Denny, Cools, Roshan, Delecroix, Clara, Hartmann, Jessica A., Kendler, Kenneth S., van de Leemput, Ingrid, van der Maas, Han L. J., van Nes, Egbert, Mattson, Mark, McGorry, Pat D., and Nelson, Barnaby
- Subjects
DYNAMICAL systems ,MENTAL illness ,SYSTEMS theory ,CHAOS theory ,RAIN forests - Abstract
This narrative review, the second of 2 parts about a new approach to the diagnosis and treatment of psychiatric disorders that is based on dynamical systems theory, describes the implications of evidence for the practical applicability of this theory and its quantitative tools. Importance: Dynamical systems theory is widely used to explain tipping points, cycles, and chaos in complex systems ranging from the climate to ecosystems. It has been suggested that the same theory may be used to explain the nature and dynamics of psychiatric disorders, which may come and go with symptoms changing over a lifetime. Here we review evidence for the practical applicability of this theory and its quantitative tools in psychiatry. Observations: Emerging results suggest that time series of mood and behavior may be used to monitor the resilience of patients using the same generic dynamical indicators that are now employed globally to monitor the risks of collapse of complex systems, such as tropical rainforest and tipping elements of the climate system. Other dynamical systems tools used in ecology and climate science open ways to infer personalized webs of causality for patients that may be used to identify targets for intervention. Meanwhile, experiences in ecological restoration help make sense of the occasional long-term success of short interventions. Conclusions and Relevance: Those observations, while promising, evoke follow-up questions on how best to collect dynamic data, infer informative timescales, construct mechanistic models, and measure the effect of interventions on resilience. Done well, monitoring resilience to inform well-timed interventions may be integrated into approaches that give patients an active role in the lifelong challenge of managing their resilience and knowing when to seek professional help. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. A Dynamical Systems View of Psychiatric Disorders—Theory: A Review.
- Author
-
Scheffer, Marten, Bockting, Claudi L., Borsboom, Denny, Cools, Roshan, Delecroix, Clara, Hartmann, Jessica A., Kendler, Kenneth S., van de Leemput, Ingrid, van der Maas, Han L. J., van Nes, Egbert, Mattson, Mark, McGorry, Pat D., and Nelson, Barnaby
- Subjects
DYNAMICAL systems ,MENTAL illness ,SYSTEMS theory ,CHAOS theory ,RAIN forests - Abstract
This narrative review describes a new approach to the diagnosis and treatment of psychiatric disorders that is based on dynamical systems theory, which addresses the concepts of tipping points, cycles, and chaos in complex systems. Importance: Psychiatric disorders may come and go with symptoms changing over a lifetime. This suggests the need for a paradigm shift in diagnosis and treatment. Here we present a fresh look inspired by dynamical systems theory. This theory is used widely to explain tipping points, cycles, and chaos in complex systems ranging from the climate to ecosystems. Observations: In the dynamical systems view, we propose the healthy state has a basin of attraction representing its resilience, while disorders are alternative attractors in which the system can become trapped. Rather than an immutable trait, resilience in this approach is a dynamical property. Recent work has demonstrated the universality of generic dynamical indicators of resilience that are now employed globally to monitor the risks of collapse of complex systems, such as tropical rainforests and tipping elements of the climate system. Other dynamical systems tools are used in ecology and climate science to infer causality from time series. Moreover, experiences in ecological restoration confirm the theoretical prediction that under some conditions, short interventions may invoke long-term success when they flip the system into an alternative basin of attraction. All this implies practical applications for psychiatry, as are discussed in part 2 of this article. Conclusions and Relevance: Work in the field of dynamical systems points to novel ways of inferring causality and quantifying resilience from time series. Those approaches have now been tried and tested in a range of complex systems. The same tools may help monitoring and managing resilience of the healthy state as well as psychiatric disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study
- Author
-
Sarah Kerins, Judith Nottage, Gonzalo Salazar de Pablo, Matthew J. Kempton, Stefania Tognin, Dorien H. Niemann, Lieuwe de Haan, Thérèse van Amelsvoort, Jun Soo Kwon, Barnaby Nelson, Romina Mizrahi, Philip McGuire, Paolo Fusar-Poli, The PSYSCAN Consortium, Matthew Kempton, Gemma Modinos, Kate Merritt, Alexis E. Cullen, Andrea Mechelli, Paola Dazzan, George Gifford, Natalia Petros, Mathilde Antoniades, Andrea De Micheli, Sandra Vieira, Tom Spencer, Rene Kahn, Arija Maat, Erika van Hell, Inge Winter, Frederike Schirmbeck, Benedicto Crespo-Facorro, Diana Tordesillas-Gutierrez, Esther Setien-Suero, Rosa Ayesa-Arriola, Paula Suarez-Pinilla, Victor Ortiz Garcia-de la foz, Birte Glenthøj, Mikkel Erlang Sørensen, Bjørn H. Ebdrup, Karen Tangmose, Helle Schæbel, Egill Rostrup, Oliver Gruber, Anja Richter, Bernd Krämer, Therese van Amelsvoort, Bea Campforts, Machteld Marcelis, Claudia Vingerhoets, Celso Arango, Covandonga M. Díaz-Caneja, Miriam Ayora, Joost Janssen, Roberto Rodríguez-Jiménez, Marina Díaz-Marsá, Tilo Kircher, Irina Falkenberg, Florian Bitsch, Jens Sommer, Patrick McGorry, Paul Amminger, Meredith McHugh, Suzie Lavoie, Jessica Spark, Rebekah Street, Silvana Galderisi, Armida Mucci, Paola Bucci, Giuseppe Piegari, Daria Pietrafesa, Luigi Giuliani, Rodrigo Bressan, André Zugman, Ary Gadelha, Graccielle Rodrigues da Cunha, Kang Ik Kevin Cho, Tae Young Lee, Minah Kim, Sun-Young Moon, Silvia Kyungjin Lho, Mark Weiser, Michael Kiang, Cory Gerritsen, Margaret Maheandiran, Sarah Ahmed, Ivana Prce, Jenny Lepock, Gabriele Sachs, Matthäus Willeit, Marzena Lenczowski, Ullrich Sauerzopf, Ana Weidenauer, Julia Furtner-Srajer, Matthias Kirschner, Anke Maatz, Achim Burrer, Philipp Stämpfli, Naemi Huber, and Kawohl Wolfram
- Subjects
EEG ,CHR-P ,multi-site ,biomarkers ,psychosis prediction ,Psychiatry ,RC435-571 - Abstract
BackgroundThe clinical high-risk for psychosis (CHR-P) paradigm was introduced to detect individuals at risk of developing psychosis and to establish preventive strategies. While current prediction of outcomes in the CHR-P state is based mostly on the clinical assessment of presenting features, several emerging biomarkers have been investigated in an attempt to stratify CHR-P individuals according to their individual trajectories and refine the diagnostic process. However, heterogeneity across subgroups is a key challenge that has limited the impact of the CHR-P prediction strategies, as the clinical validity of the current research is limited by a lack of external validation across sites and modalities. Despite these challenges, electroencephalography (EEG) biomarkers have been studied in this field and evidence suggests that EEG used in combination with clinical assessments may be a key measure for improving diagnostic and prognostic accuracy in the CHR-P state. The PSYSCAN EEG study is an international, multi-site, multimodal longitudinal project that aims to advance knowledge in this field.MethodsParticipants at 6 international sites take part in an EEG protocol including EEG recording, cognitive and clinical assessments. CHR-P participants will be followed up after 2 years and subcategorised depending on their illness progression regarding transition to psychosis. Differences will be sought between CHR-P individuals and healthy controls and between CHR-P individuals who transition and those who do not transition to psychosis using data driven computational analyses.DiscussionThis protocol addresses the challenges faced by previous studies of this kind to enable valid identification of predictive EEG biomarkers which will be combined with other biomarkers across sites to develop a prognostic tool in CHR-P. The PSYSCAN EEG study aims to pave the way for incorporating EEG biomarkers in the assessment of CHR-P individuals, to refine the diagnostic process and help to stratify CHR-P subjects according to risk of transition. This may improve our understanding of the CHR-P state and therefore aid the development of more personalized treatment strategies.
- Published
- 2022
- Full Text
- View/download PDF
48. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin
- Author
-
Michael Berk, Mohammadreza Mohebbi, Olivia M. Dean, Sue M. Cotton, Andrew M. Chanen, Seetal Dodd, Aswin Ratheesh, G. Paul Amminger, Mark Phelan, Amber Weller, Andrew Mackinnon, Francesco Giorlando, Shelley Baird, Lisa Incerti, Rachel E. Brodie, Natalie O. Ferguson, Simon Rice, Miriam R. Schäfer, Edward Mullen, Sarah Hetrick, Melissa Kerr, Susy M. Harrigan, Amelia L. Quinn, Catherine Mazza, Patrick McGorry, and Christopher G. Davey
- Subjects
Depression ,Treatment ,Statins ,Medicine - Abstract
Abstract Background Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, compared with placebo, reduced depressive symptoms in young people (15–25 years). Methods YoDA-A, Youth Depression Alleviation with Anti-inflammatory Agents, was a 12-week triple-blind, randomised, controlled trial. Participants were young people (aged 15–25 years) with moderate to severe MDD (MADRS mean at baseline 32.5 ± 6.0; N = 130; age 20.2 ± 2.6; 60% female), recruited between June 2013 and June 2017 across six sites in Victoria, Australia. In addition to treatment as usual, participants were randomised to receive aspirin (n = 40), rosuvastatin (n = 48), or placebo (n = 42), with assessments at baseline and weeks 4, 8, 12, and 26. The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to week 12. Results At the a priori primary endpoint of MADRS differential change from baseline at week 12, there was no significant difference between aspirin and placebo (1.9, 95% CI (− 2.8, 6.6), p = 0.433), or rosuvastatin and placebo (− 4.2, 95% CI (− 9.1, 0.6), p = 0.089). For rosuvastatin, secondary outcomes on self-rated depression and global impression, quality of life, functioning, and mania were not significantly different from placebo. Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12. Statins were superior to aspirin on the MADRS, the Clinical Global Impressions Severity Scale (CGI-S), and the Negative Problem Orientation Questionnaire scale (NPOQ) at week 12. Conclusions The addition of either aspirin or rosuvastatin did not to confer any beneficial effect over and above routine treatment for depression in young people. Exploratory comparisons of secondary outcomes provide limited support for a potential therapeutic role for adjunctive rosuvastatin, but not for aspirin, in youth depression. Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12613000112763. Registered on 30/01/2013.
- Published
- 2020
- Full Text
- View/download PDF
49. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
- Author
-
S. M. Cotton, M. Berk, A. Watson, S. Wood, K. Allott, C. F. Bartholomeusz, C. C. Bortolasci, K. Walder, B. O’Donoghue, O. M. Dean, A. Chanen, G. P. Amminger, P. D. McGorry, A. Burnside, J. Uren, A. Ratheesh, and S. Dodd
- Subjects
First-episode psychosis ,Psychotic disorders ,Neuroprotective agents ,Treatment ,Outcome ,N-acetylcysteine ,Medicine (General) ,R5-920 - Abstract
Abstract Background First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown that the antioxidant amino acid N-acetylcysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary aim of this study is to determine the efficacy of treatment with adjunctive NAC (2 g/day for 26 weeks) compared with placebo to improve psychiatric symptoms in young people experiencing FEP. Secondary aims are to explore the neurobiological mechanisms underpinning NAC and how they relate to various clinical and functional outcomes at 26- and 52-week follow-ups. Methods/design ENACT is a 26-week, randomised controlled trial of adjunctive NAC versus placebo, with a 26-week non-treatment follow-up period, for FEP. We will be recruiting 162 young people aged 15–25 years who have recently presented to, and are being treated at, the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. The primary outcome is the Total Score on the Positive and Negative Syndrome Scale which will be administered at baseline, and weeks 4, 8, 12, 26 (primary endpoint), and 52 (end of study). Secondary outcomes include: symptomatology, functioning, quality of life, neurocognition, blood-derived measures of: inflammation, oxidative and nitrosative stress, and magnetic resonance spectroscopy measures of glutathione concentration. Discussion Targeted drug development for FEP to date has generally not involved the exploration of neuroprotective agents. This study has the potential to offer a new, safe, and efficacious treatment for people with FEP, leading to better treatment outcomes. Additionally, the neuroprotective dimension of this study may lead to a better long-term prognosis for people with FEP. It has the potential to uncover a novel treatment that targets the neurobiological mechanisms of FEP and, if successful, will be a major advance for psychiatry. Trial registration Australian New Zealand Clinical Trials Registry, ID: ACTRN12618000413224. Registered on 21 March 2018.
- Published
- 2019
- Full Text
- View/download PDF
50. Perceived Benefits of a Guided Exercise Program Among Older Adults
- Author
-
Emilia Patricia T. Zarco MD, MEd, Michele Aquino MS, DPT, John Petrizzo DPT, John Wygand MA, and Amy McGorry PT, DPT, MTC
- Subjects
Geriatrics ,RC952-954.6 - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.